Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.
We report nine cases where fluoxetine (FX) (20 mg/day) was added to maintenance treatment with methadone (MTD) (dose range: 30-100 mg) in addicts with affective disorders. MTD plasma levels were measured before and after treatment with FX under steady-state conditions. Among the nine patients, two also received fluvoxamine (FLVX) at different times. Although it is possible that in some patients a moderate FX-MTD interaction occurs, resulting in increased plasma levels of MTD, this interaction is certainly less marked than that between FLVX and MTD and unlikely to have clinical consequences.
Bertschy
G
G
Département Universitaire de Psychiatrie Adulte, Lausanne, Switzerland.
Eap
C B
CB
Powell
K
K
Baumann
P
P
D000328:Adult; D000701:Analgesics, Opioid / Q000493:pharmacokinetics*; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016666:Fluvoxamine / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019964:Mood Disorders / Q000097:blood* / Q000188:drug therapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics; D019966:Substance-Related Disorders / Q000097:blood* / Q000534:rehabilitation
D000701:Analgesics, Opioid; D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D016666:Fluvoxamine; D008691:Methadone; D017367:Selective Serotonin Reuptake Inhibitors